New Two-Pronged attack aims to save insulin cells in kids with diabetes
NCT ID NCT05742243
Summary
This study tested whether combining two immune-modifying treatments—abatacept (a weekly injection) and nasal insulin (a spray)—could help protect the pancreas's remaining insulin-producing cells in children and young adults recently diagnosed with type 1 diabetes. The goal was to slow the disease's progression, making daily blood sugar management easier and potentially reducing the need for injected insulin. The treatment lasted 48 weeks, followed by another year of monitoring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Perth Children's Hospital
Nedlands, Western Australia, 6009, Australia
-
Queensland Children's Hospital
South Brisbane, Queensland, 4101, Australia
-
The Children's Hospital at Westmead
Westmead, New South Wales, 2145, Australia
-
The Royal Children's Hospital
Parkville, Victoria, 3052, Australia
-
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
Women's and Children's Hospital
North Adelaide, South Australia, 5006, Australia
Conditions
Explore the condition pages connected to this study.